Dual isotope labeling: Conjugation of 32P-oligonucleotides with 18F-aryltrifluoroborate via copper(I) catalyzed cycloaddition
摘要:
A one-pot-two-step labeling of an oligonucleotide with an F-18-ArBF3 (aryltrifluoroborate) radioprosthetic is reported herein. In order to characterize labeling in terms of radiochemistry, phosphorus-32 was also introduced to the 50-terminus of the oligonucleotide via enzymatic phosphorylation. A pendant azide group was subsequently conjugated to the 50-phosphate of the oligonucleotide. Copper(I) catalyzed [ 2+ 3] cycloaddition was undertaken to conjugate an alkyne-bearing(18)F-ArBF3 to the oligonucleotide. Following polyacrylamide gel electrophoresis, this doubly-labeled bioconjugate exhibited decay properties of both the phosphorus-32 and fluorine-18, that were confirmed by autoradiography at selected lengths of time, which in turn provided concrete evidence of successful conjugation. These results are corroborated by HPLC analysis of the labeled material. Taken together this work demonstrates viable use of F-18-ArBF3 prosthetics for labeling oligonucleotides for use in PET imaging. (C) 2013 Elsevier Ltd. All rights reserved.
Synthesis and characterization of 2,6-difluoro-4-carboxyphenylboronic acid and a biotin derivative thereof as captors of anionic aqueous [18F]-fluoride for the preparation of [18F/19F]-labeled aryltrifluoroborates with high kinetic stability
摘要:
Arylboronic esters are readily converted to aryltrifluoroborates in the presence of aqueous fluoride. As such these represent attractive synthetic precursors that afford one-step labeling with [F-18]-fluoride for the generation of PET reagents. Herein we present the synthesis of a heretofore undisclosed arylboronic ester that is converted to its corresponding trifluoroborate. Essential for contemplating its use in PET imaging is the demonstration of kinetic resistance to solvolytic defluoridation. (C) 2008 Published by Elsevier Ltd.
4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
申请人:Merck Sharp & Dohme Corp.
公开号:US20150218096A1
公开(公告)日:2015-08-06
The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.